Bio-Works has confirmed a new order for a customized, prepacked solution worth SEK 0.8 million to be used in a viral vector manufacturing process. The initial order is for process validation runs, and the potential annual revenue from the project is estimated to be between SEK 3-12 million. The customer is an American contract manufacturer of gene therapy products.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.8 SEK | -1.75% | -4.76% | -60.56% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-60.56% | 10.28M | |
-4.02% | 184B | |
-0.75% | 108B | |
-2.97% | 67.82B | |
+4.48% | 51.05B | |
+9.09% | 44.67B | |
+3.74% | 41.78B | |
+3.12% | 26.78B | |
+4.10% | 26.59B | |
+15.38% | 25.86B |
- Stock Market
- Equities
- BIOWKS Stock
- News Bio-Works Technologies AB
- Bio-Works Secures SEK 0.8 Million Order for Gene Therapy Manufacturing